Piramal Pharma Limited reported its FY26 financial results, highlighting a transitional year impacted by external market factors. While full-year revenue stood at ₹8,869 crore, the company exited the year with stronger momentum. Strategic initiatives, including the Kenalog® acquisition and increased focus on high-growth CDMO areas, position the firm for growth in FY27. The company remains committed to its long-term strategy, prioritizing operational excellence and expanded capacities in its key business segments.
Consolidated Financial Performance
For the financial year ended March 31, 2026, Piramal Pharma recorded revenue from operations of ₹8,869 crore, reflecting a 3% year-on-year change. The EBITDA for the year was ₹1,135 crore, with the company focusing on cost optimization and operational excellence to navigate the fiscal challenges. Despite reporting a net loss after exceptional items, management emphasized that the year was shaped by specific external disruptions and inventory destocking impacts that have now begun to normalize.
Strategic Segment Highlights
The company’s diverse business portfolio demonstrated varying levels of resilience and growth:
- CDMO: The business is seeing a rebound with 75% YoY growth in US biopharma funding (H2FY26) and a Net Promoter Score of 60. Investment of US$90 million in sterile injectable and payload-linker capacities remains on track.
- Complex Hospital Generics (CHG): The segment saw 3% revenue growth, bolstered by the Kenalog® acquisition and a dominant 47% market share in the US Sevoflurane market.
- Consumer Healthcare (PCH): This division grew by 17%, with Power Brands now contributing 52% to segment sales, supported by a 48% growth in e-commerce channels.
Future Outlook and Growth Drivers
Looking ahead to FY27, the company remains optimistic about a return to growth. Leadership highlighted that the recovery in biopharma funding and the successful expansion of the distribution network are key pillars for the upcoming year. With US$94 million in total Capex invested in FY26 for growth and maintenance, Piramal Pharma is scaling its capabilities, particularly in the US market, to capture increased demand and drive accelerated growth in both EBITDA and Profit After Tax (PAT).
Source: BSE
